Evotec’s (EVO) “Buy” Rating Reaffirmed at HC Wainwright

Evotec (NASDAQ:EVO)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 106.99% from the stock’s previous close.

EVO has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Jefferies Financial Group lowered Evotec from a “buy” rating to a “hold” rating and dropped their price objective for the company from $8.70 to $3.80 in a research note on Monday, October 7th. Finally, Morgan Stanley lowered Evotec from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $15.00 to $6.00 in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.93.

Evotec Trading Down 15.6 %

Shares of NASDAQ EVO opened at $3.87 on Thursday. The business has a 50-day simple moving average of $3.50 and a two-hundred day simple moving average of $4.25. Evotec has a 52 week low of $2.85 and a 52 week high of $12.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83.

Institutional Trading of Evotec

A number of hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Evotec during the second quarter worth approximately $87,000. Cetera Advisors LLC bought a new position in shares of Evotec during the 1st quarter valued at $188,000. Clear Harbor Asset Management LLC bought a new stake in Evotec in the third quarter worth $104,000. DCF Advisers LLC boosted its position in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after buying an additional 67,156 shares during the period. Finally, Mediolanum International Funds Ltd bought a new position in shares of Evotec during the third quarter valued at about $512,000. Institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.